Abstract Pleomorphic xanthoastrocytomas with anaplastic features (PXA-As) are rare tumors about which little is known regarding clinicopathologic and molecular features. Several studies have identified BRAF V600E mutations in PXA-As, but the percentage with mutation may differ between adult and pediatric examples, and limited information exists about immunohistochemistry for isocitrate dehydrogenase 1 (IDH1). Ten cases of adult PXA-As seen at our institution since 2000 were assessed for BRAF V600E mutation by polymerase chain reaction testing (PCR) and IDH1 by immunohistochemistry. Patients ranged in age from 18-68 years; four PXA-As affected temporal lobe and two were cystic. Four patients underwent gross total resection and 9 of 10 patients received cranial irradiation and/or adjuvant chemotherapy. Five survived less than 5 years, although 2 of 5 patients died from non-tumor causes. Four long-term survivors are alive at 7.5, 9.8, 11.4, and 11.9 years post-diagnosis. Two of four long term survivors had BRAF V600E mutation: patients were ages 18 and 28 years. A 48-year-old male without BRAF mutation survives at 9.8 years, even with thalamic location; conversely a 68-year-old female with temporal lobe tumor and BRAF mutation survived 1.9 years after diagnosis. All tumors were IDH1 immunonegative. This case series details clinicopathologic features of a subset of rare PXA-As in adults. BRAF V600E mutation was identified in 50 % of these cases.
Introduction
Pleomorphic xanthoastrocytomas (PXAs) are rare WHO grade II tumors, first fully characterized by Kepes et al. [1] , which demonstrate a relatively favorable clinical course [1] [2] [3] . Pleomorphic xanthoastrocytomas with anaplastic features (PXA-A) designates a subset with more aggressive histopathologic features and more adverse prognosis, and has yet to be assigned a formal WHO grade [2] . Pleomorphic xanthoastrocytomas and PXA-As collectively constitute no more than 1 % of astrocytic tumors and are usually seen in children and young adults [1] [2] [3] , with a mean age of 26 years [3] . Nearly two-thirds of examples occur in patients less than age 25 years [3] .
Adult examples are thus uncommon, although well-documented cases have been seen in patients 40 years or older [4] [5] [6] [7] [8] [9] . Some authors have suggested a worse prognosis is associated with older patient age [9] . Pleomorphic xanthoastrocytomas with anaplastic features may arise de novo [10, 11] , or may develop anaplastic features, including necrosis and/or increased mitotic index [3] at recurrence of a previous WHO grade II PXA [3, 5, 7, [10] [11] [12] [13] [14] [15] [16] . Recent reviews, by Tekkok and Sav [14] , Okazaki et al. [15] and Vu et al. [16] , emphasize the fact that for either de novo PXA-As or for those that acquire anaplastic features at recurrence, the prognosis is often, but not invariably poor.
Which histologic feature(s) correlates best with prognosis in individual patients remains somewhat unclear. A seminal study of 71 cases and review of an additional 121 published cases of PXA by Giannini et al. [3] , led the World Health Organization (WHO) in 2007 to adopt her findings that mitotic activity of greater than or equal to five mitoses per ten high power fields (HPFs) is the sole independent predictor of overall survival by multivariate analysis [2] . A ''significant association of necrosis with survival'' was also acknowledged, although this did not reach statistical significance on multivariate analysis [2] . On univariate analysis, three categories of patients with differing recurrence-free survival and overall survival rates could be identified: those with zero mitoses, those with 1-4 and those with C5 mitoses [3] . Korshunov and Golanov [17] in their 2001 series of 34 patients were more clearly able to identify three subsets of PXAs: typical: tumors without mitoses per 20 HPFs; proliferating: tumors with mitoses but without necrosis; and malignant: tumors with elevated mitotic index and necrotic foci. There were no recurrences or death among typical tumors. In contrast, 36 % of proliferating tumors recurred and one patient died, and 5/5 malignant tumors rapidly recurred and 4/5 succumbed. Other authors have placed emphasis on necrosis [17, 18] and MIB-1/Ki-67 cell cycling rate [10] [11] [12] .
Recently, mutation in BRAF V600E at position 600, specifically V600E (NM_004333.4 c.1799T[A, hereafter referred to as BRAF V600E), has been identified as a common finding in certain central nervous system (CNS) tumors, most commonly in PXAs (WHO grade II) and PXA-As. The same mutation has also been found in ganglioglioma and extra-cerebellar pilocytic astrocytoma [19] [20] [21] . Among CNS tumors, the presence of BRAF V600E may be helpful in distinguishing PXAs from diffuse astrocytic tumors WHO grades II, III, and IV [21] since the latter almost always lack this finding [19] .
In contrast, a common mutation in IDH1 is typical of the majority of diffuse astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas of WHO grades II and III [22] . Immunohistochemical (IHC) staining for IDH1 correlates strongly with the IDH1 mutational status as assessed by polymerase chain reaction testing [23] and thus can serve as a cost-and time-effective substitute.
Relatively few examples of adult PXA-As have been studied for BRAF mutational status. Studies by Schindler et al. [20] hint that there may be age-related differences in BRAF V600E mutational status, based on the fact that, in their study, 38 % of adult pleomorphic xanthoastrocytomas with anaplastic features showed this mutation (5/13 adult cases), compared to 100 % of pediatric PXA-As (10/10 pediatric cases). PXA-As showed this mutation (5/13 adult cases), compared to 100 % of pediatric PXA-As (10/10 pediatric cases) [19] .
Finally, although IDH1 immunoreactivity appears to be a signature of diffuse astrocytomas and not PXAs, large numbers of adult PXA-A cases have also not been assessed [22] . We undertook this study of PXA-As to address these issues. We confined our work to a series of adult patients well-known within our system for which treatment data and long term clinical followup could be obtained.
Materials and methods

Case accrual
Institutional research review board approval was obtained for this study. Cases were identified by diagnosis from our pathology department databank and/or personal files of the authors for the years 2000-2011, inclusive. Medical records were reviewed by the neuro-oncologist (DMD) to obtain neuroimaging features, treatment regimens, and survival data. Followup data was sought for all patients, and patients recorded as alive or dead. Those who died were recorded as succumbing either to disease (i.e., their PXA-A) or from other causes. For those patients still living, survival data was calculated from time of PXA-A diagnosis to 3/2012, the closure of study (Table 1) .
All slides were re-reviewed for diagnosis confirmation (BKD). For diagnosis of PXA-A, criteria identified by Giannini et al. [2, 3] were utilized. All cases in this study contained the major histologic findings previously identified as essential to diagnosis, including multinucleated pleomorphic large cells (seen in 92 % of PXA cases in her study [3] ), GFAP immunoreactivity (98 % of cases), granular bodies (93 %: eosinophilic 81 %/pale 71 %), lymphocytic collections (83 % of cases), foci of increased reticulin (81 %), and xanthic cells (66 % of cases). Most cases were quite stereotypic and similar in features. All cases had pleomorphic cells and GFAP immunoreactivity. Granular bodies, especially eosinophilic, refractile, dropletlike, eosinophilic, Periodic acid Schiff-positive (PASpositive) granular bodies were specifically sought and tabulated (see Table 2 ). As noted by Giannini et al. [3] , ''although it was not stressed in the original description of PXA or in the WHO monograph, granular bodies of varying size, texture, and eosinophilia are a regular feature of this tumor''. In our own experience, the presence of granular bodies has been the single most distinctive and helpful clue since they are usually not identified in glioblastomas (lipidized, giant cell or ordinary), the main tumor type in the differential diagnosis for PXA-A.
Methods for histology
For light microscopy, tumor sections were cut at four microns and stained with hematoxylin and eosin (H&E), reticulin (Gordon Sweet reticulum II), and periodic acid Schiff in selected cases where eosinophilic granular bodies were rare on H&E. Immunohistochemistry for glial fibrillary acidic protein (GFAP, Dako #M761, Carpinteria, CA, monoclonal, 1:100 dilution) and synaptophysin (Ventana 790-4286, Tucson, AZ, rabbit monoclonal, Pre Dilute) was additionally utilized for diagnosis.
Immunohistochemistry for IDH1 (DianovaHistoBio, Miami Beach, Florida, clone H09, monoclonal, 1:40 dilution) and MIB-1 cell cycle labeling (Ventana 790-4286, Tucson, AZ, rabbit monoclonal, Pre Dilute) was conducted on all cases. All assessments for IHC were performed on the first resection at which PXA-A diagnosis was made.
Mitotic figures were counted at high power objective (409), with ten consecutive fields counted after identifying a mitosis. Considerable variation in mitotic rates from one region to the next was encountered in all cases, a feature previously well described by others in the literature [3, 24] . The presence or absence of eosinophilic granular bodies was assessed and recorded as present, rare, single, or absent on H&E. In select cases PAS was performed. Necrosis and microvascular proliferation were also assessed and recorded, detailed in the Table 2 . MIB-1 was assessed as percentage of immuno-positive tumor nuclei on 1000 cell counts, avoiding non-tumoral cells such as lymphocytes in the counts.
Methods for V600E BRAF mutational analysis
Blocks (or in one case unstained slides with scrape of tissue) with PXA morphology were specifically targeted for assessment. In the case of the scraped slides, paraffin sections were thoroughly deparaffinized in xylene, hydrated through graded alcohols to water and stained with Gill's hematoxylin. Slides were covered with glycerol to prevent cell dispersion and isolated under dissecting microscope using a scalpel point or hollow borosilicate glass pipette. The scraped material was washed in PBS and digested in proteinase K overnight at 37°C in ATL Buffer (Qiagen Inc.). DNA was then isolated using QIAamp DNA FFPE extraction kit (cat #56404) according to manufacturer instruction.
In the case of paraffin tissue blocks (remaining cases), paraffin scrolls were deparaffinized in xylene as above, followed by reconstitution in graded alcohols and PBS and treated in parallel fashion. DNA yields were then quantified using a Nanodrop spectrophotometer ND-1000 (Thermo Fisher Scientific Inc., Waltham, MA).
For direct sequencing, approximately 10 ng of template DNA was PCR amplified using 5 pmol each of forward
TM Robust HotStart Enzyme and PCR master mix with KAPA TM dNTP mix (KAPA Biosystems cat# KK5525 and KK1017) in a 25 ll reaction. Polymerase chain reaction was performed on an ABI 9700 thermocycler with an initial denaturing step at 95°C, followed by 20 cycles of touchdown PCR (starting annealing temperature of 65°C, decremented 0.5°C per cycle) and 25 cycles at 94°C denaturation, 55°C annealing, and 72°C extension finished by a 10 min 72°C final extension. The resultant PCR products were purified with the QIAquick 96 well PCR cleanup kit (Qiagen cat# 28106). The purified PCR products were sequenced in forward and reverse directions using an ABI 3730 automated sequencer that utilizes BigDye Terminator Version 1.1 (Applied Biosystems). Each chromatogram was visually inspected for any abnormalities, using NM_004333.4 as a reference sequence, with particular attention directed to codon 600. Sequences were also evaluated using Mutation Surveyor software (Soft Genetics, State College, PA). Mutations were determined to be present when peaks reached a threshold value above baseline calculated from background level, combined with visual inspection of the chromatogram.
Results
Demographic, clinical, treatment, and survival data is listed in Table 1 , with histologic and genetic features detailed in Table 2 . Ten patients were identified (five females, five males). Patients ranged in age from 18-68 years; four PXA-As affected temporal lobe and two tumors were cystic. Patients had been treated as high grade gliomas with surgery, external beam irradiation, and chemotherapy, except for one patient who refused treatment beyond subtotal resection (patient #7, see Table 1 ), and another who could not tolerate a full course of radiotherapy (patient #9). Data was not available for two cases (see Table 1 ). Most patients receiving chemotherapy had been treated with standard temozolomide and four had undergone a second surgical resection after the PXA-A diagnosis (see Table 1 ). One patient had a past medical history of neurofibromatosis type I (patient #1), one had colon cancer (patient #2), and one had a previous diagnosis of a high grade glioma antecedent to their PXA-A diagnosis at our institution (patient #8). Patient #8 had been diagnosed with anaplastic astrocytoma 3 years before. Slides from this surgical procedure performed at an outside facility were not available for review. The remaining nine patients with PXA-As occurred de novo.
Tumors predominantly affected frontal or temporal lobes (see Table 1 ), with a single case involving subcortical gray matter (patient # 6). The range of neuroimaging features is illustrated in Fig. 1 . Since a significant number of our cases had first been diagnosed with PXA-As in the early 2000s, four-fifths of the survivors have been followed for [7 years (range: 7 years, 5 months to 11 years, 9 months). The final patient was diagnosed more recently and, as of the study closure time point of 3/2012, had a clinical followup time of 7 months (see Table 1 ). Of the five survivors known to be alive at study closure, mean clinical followup time has been 8 years, 5 months, with a median of 9 years, 8 months. Nine of the ten patients in this cohort were able to followed to demise or to study closure date; the tenth patient (patient #8) was lost to followup 2 years after diagnosis.
Microscopically, the majority of cases showed classic PXA areas adjacent to higher-grade glioma showing variable mitotic activity, necrosis, some microvascular proliferation (see Table 2 ). In seven cases the two areas were relatively distinct. In three examples (patients #2, 4, 7), however, there was a more intimate blend between the neoplastic pleomorphic cells with xanthic or granular cell changes and smaller cells manifesting ordinary high grade glial tumor features. In some cases, the higher-grade glioma manifested small cell glioblastoma features (examples: patients #1, 3, 10), a feature described years ago [25, 26] . In these instances, the areas of high-grade glioma were completely indistinguishable from ordinary high-grade gliomas. This raised the obvious issue of whether sampling #1 (a, c, e,  g ) (a 27-year-old female with relatively separate classic PXA and high grade glioma areas of tumor in whom no BRAF mutation was detected yet is a 10? year survivor) versus patient #3 (b, d, f, h) (a 68-year-old female also with relatively separate classic PXA and high grade glioma areas in whom BRAF mutation was detected yet survived less than 2 years). Note typical features of PXA including brisk non neoplastic lymphocytic collections (a, b), large pleomorphic cells (b inset, c), focally increased reticulin fibers (d), eosinophilic granular bodies (arrows, e, f) and negative immunostaining for IDH1 (g, h). Hematoxylin and eosin (a 9100, b 9400, b inset 9600, c 9600, e 9600, b 9600), reticulin stain (d 9200), and immunostaining for IDH1 with light hematoxylin counterstain (g, h, both 9400)
indistinguishable based on BRAF mutational status, at least in our small case series. The histologic features seen in these rare adult PXA-As are illustrated in Figs. 2 and 3 . The PXA features of two representative patients, one with, and one without, BRAF mutation, are shown in Fig. 2 . Histologic features for high grade glioma areas of these tumors are shown in Fig. 3 . Four patients were known to have recurrences of their tumors within the study time period (see Table 1 , patients #1, 4, 5, and 6). MIB-1 indices of the PXA-As at the time of the initial resections, for these patients with known recurrences were not obviously higher than for those without known recurrences. These four patients had MIB-1 rates, respectively, of 9, 8.5, 9, and 8.5 % ( Table 2 ). In contrast, patient #7 had an initial MIB-1 rate of 5.5 % and died of his disease within 1.7 years of initial diagnosis. Small cohort size precluded any definitive conclusions about MIB-1 rate and tendency for recurrence or overall survival.
Five patients who succumbed survived less than 5 years, although two of these five died from non-tumor causes (see Table 1 ). Long term survivors are alive at 7-11? years post-diagnosis. Of these long term survivors, two of four had BRAF V600E mutation in the tumor: these two patients were ages 18 and 28 years. Another young patient, 22 years old, did possess the BRAF V600E mutation, and succumbed to his disease 1.7 years after diagnosis; he received only subtotal resection and was the single patient who had refused postoperative chemo-or radiotherapy.
In our series, three of four patients over age 45 years were BRAF negative: a 68-year-old did show BRAF mutation; her survival after diagnosis was 1.9 years. A 48-year-old male without BRAF mutation survives at 9.8 years, even with thalamic location. The small sample size limits any meaningful correlation between BRAF mutational status and survival.
Discussion
We have been interested in PXA-As since 2001 when we encountered a particularly tragic case where his treatment, not tumor, led to his demise [27] . This 34-year-old man developed a radiation-induced CNS sarcoma 11 years after receiving cranial irradiation (but no chemotherapy) for a ''glioblastoma'' diagnosed at an outside facility [27] . On obtaining his original 1990 slides, the tumor, in retrospect, proved to be a PXA-A with copious numbers of eosinophilic granular bodies, focal lymphocytic collections, xanthic cells, Rosenthal fibers, and elongate spindle tumor cells, all features of PXA, but with superimposed necrosis, microvascular proliferation, and mitoses, features of PXA-A. He succumbed less than 1 year later to his radiationinduced sarcoma despite several therapies. Clearly in this example, the risks of overly aggressive treatment were obvious. Giannini et al. [3] also mention a patient with a high mitotic index but no necrosis at first surgery who died 5.7 years after primary surgery from a contralateral postirradiation anaplastic oligodendroglioma. On the other hand, the single patient in our current study in whom only a subtotal resection could be achieved and who declined any adjuvant treatment, succumbed after 1.7 years, suggesting that adjuvant radio/chemotherapy may have therapeutic benefit. At our institution, additional therapy has always been recommended, and almost always received.
Our study was confined to PXA-As in adults, which make up a smaller subset of an already-rare glioma tumor type [3] , explaining the limited case numbers in our study. Most of our cases were de novo PXA-As. Pleomorphic xanthoastrocytomas with anaplastic features may occur de novo with anaplastic features at first resection or may evolve from PXA grade II to PXA-A, but both have variable, but often poor, outcomes [3, [13] [14] [15] . One of our cases had been biopsied elsewhere and diagnosed as anaplastic astrocytoma; sampling error cannot be excluded since the high grade glioma portion of PXA-As is usually indistinguishable from ordinary diffuse high grade glioma, a point made many years ago by Kepes et al. [25] and Macaulay et al. [26] .
All of our cases met criteria for PXA-A based on either mitotic rate [5/10 HPFs or presence of necrosis, and most examples had both (see Table 2 ). In addition, we conducted MIB-1 immunostaining on all cases. The likely importance of MIB-1 cell cycle labeling was anticipated by others in smaller series [10] [11] [12] and indeed, rates above 5.5 % were found in all adult PXA-A cases in this series. MIB-1 may assist in distinguishing PXA-A versus PXA, WHO grade II, given the wide variation in distribution of mitotic figures in these cases, as noted previously [3, 27] . In addition, it should be noted that some patients have manifested adverse clinical outcome [10] even when fewer than the five mitoses/ten HPFs (recommended as a criteria for PXA-A diagnosis [2, 3] ) have been identified; these did, however, have modestly elevated MIB-1 rates of 4.9 and 5.4 % [10] . Fig. 3 Direct comparison between high grade glioma areas in patient #1 (a, c, e, g) (a 27-year-old female with relatively separate classic PXA and high grade glioma areas of tumor in whom no BRAF mutation was detected yet is a 10? year survivor) versus patient #3 (b, d, f, h) (a 68-year-old female also with relatively separate classic PXA and high grade glioma areas in whom BRAF mutation was detected yet survived less than 2 years). Note hypercellularity (a, b, c, d), necrosis (arrows, a, b), microvascular proliferation (arrows, c, d), vascular thrombosis (arrows e, f), and elevated MIB-1 cell cycling rate (g, h). Hematoxylin and eosin (a 9100, b 9200, c 9400, d 9200, e 9400, f 9100) and immunostaining for MIB-1 with light hematoxylin counterstain (g, h both 400) While our oldest patient, a 68-year-old woman, succumbed within 2 years of diagnosis, our next-oldest patient has survived for more than 9 years. Thus, we cannot reach the same conclusion as Ng et al. [9] that advanced patient age is automatically a negative prognostic factor in adult PXA-As.
Similar to previous research [19] [20] [21] , BRAF V600E mutation was not seen in 100 % of our adult PXA-As. In our study, 50 % (5/10) PXA-As demonstrated the mutation. Schindler et al. [20] investigated a large number of PXAs (64: 38 adult / 26 pediatric) and PXA-As (23: 13 adult / 10 pediatric) and found the mutation in 66 % of PXAs overall (63 % adult, 69 % pediatric) and 65 % of PXA-As (38 % adult, 100 % pediatric). In contrast, DiasSantagata et al. [22] found the mutation in 60 % of WHO grade II PXAs, but only in one of six PXA-As. Differences may relate to the fact that only six PXA-As were available for analysis in the latter study [21] . Alternatively, the fact that all six were adults, as opposed to pediatric patients, and 5/6 were 40 years of age or older, including a 62.1-year-old female and an 86.8-year-old male, may also have influenced results [21] . Thus, there may be some differences for BRAF V600E mutation status in adult versus pediatric PXA-As. Although limited by the small number of cases, the current study contributes additional data to the issue of percentage of adult PXA-As with this mutation.
Thus, up to one-third of PXAs and PXA-As appear to be negative for BRAF V600E mutation and it is currently unclear if one, or more, as yet undiscovered genomic alterations might be present in this subpopulation without BRAF V600E mutation. Dougherty et al. [21] noted that negative PXAs and PXA-As did not show KIAA1549-BRAF fusions. At least in our study, we do not feel that regional heterogeneity accounts for the presence or absence of BRAF V600E mutation in our patients, since, in each case, the tissue block with the best morphologic features of PXA was selected for mutational analysis and each block was confirmed to have the minimum tumor cellularity to have confidence in the sequencing assay. Whether there is heterogeneity at the single cell level cannot be discerned with this sequencing technique.
Finally, our study of PXA-As contributes to the literature on IDH1 status in these rare tumors. All of our cases were IDH1 negative by immunohistochemistry. Balss et al. [23] assessed a total of 685 brain tumors, seven of which were PXAs WHO grade II and all seven are negative for IDH1 mutation. We now add to the literature ten PXA-As, all in adults that are also negative for IDH1.
